In the Australian pharmaceutical industry, there were 9 M&A deals announced in Q1 2024, worth a total value of $188.3m, according to GlobalData’s Deals Database. The $131.1m acquisition of CH2 Holdings by Paragon Care was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q1 2024 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, M&A activity in Australia decreased by 32% in Q1 2024 compared with the previous quarter’s total of $276.3m and fell by 78% as compared to Q1 2023. Related deal volume increased by 29% in Q1 2024 versus the previous quarter and was 13% higher than in Q1 2023.
The top-ranked financial advisors supporting these M&A deals in Australia in Q1 2024 were Clairfield International; Gresham House; Lazard with 1, 1, 1 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Australia in Q1 2024 were Bird & Bird; Bredin Prat & Associates; Herbert Smith Freehills with 1, 1, 1 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q1 2024 – Thematic Intelligence, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.